Business Wire

WHOOP Broadens WHOOP Advanced Labs Offering, Announcing a Women’s Health Specialized Blood Biomarker Panel

10.3.2026 11:00:00 CET | Business Wire | Press release

Share

WHOOP deepens investment in women’s physiology with clinically meaningful lab testing, predictive symptom modeling, and new Menstrual Cycle White Paper

WHOOP, the human performance company, today unveiled multiple initiatives and new clinically-backed features, including the coming launch of the company’s Women's Health Specialized Blood Biomarker Panel. Building on the WHOOP Advanced Labs Baseline Panel launched last year, the Women’s Health Specialized Blood Biomarker Panel adds 11 clinically backed, female-specific blood biomarkers that expand insight into areas that are frequently under-measured or misinterpreted in traditional women’s health testing. WHOOP has also announced a new Hormonal Symptom Insights and Predictions update, along with a comprehensive Menstrual Cycle White Paper detailing the science behind its cycle modeling.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260310966566/en/

WHOOP Broadens WHOOP Advanced Labs Offering, Announcing a Women’s Health Specialized Blood Biomarker Panel

These initiatives reflect the company’s commitment to advancing women’s health in an area that has historically been under-researched and underrepresented in data, clinical standards, and performance science. Women represent a growing share of new WHOOP members, with 150% year-over-year growth, signaling increasing demand for health insights that account for hormonal dynamics, training response, and long-term health outcomes. Women also engage with WHOOP AI approximately 30% more than male members, reflecting strong demand for intelligent, personalized women’s health support.

“Unlike solutions that focus on isolated conditions or single life stages, WHOOP delivers a connected health experience informed by one of the world’s largest datasets on women’s physiology,” said Alex Vannoni, Head of Healthcare Product at WHOOP. “We’re not just helping women track their cycles. We’re helping them understand how their physiology evolves over time - and giving them tools to act on it.”

WHOOP Advanced Labs: Women’s Health Specialized Panel

The Advanced Labs baseline and new Women’s Health Specialized Panel create a progressive, female-first testing pathway that supports women across all life stages.

The new panel, launching next month, includes critical biomarkers that dive deeper into cycle regulation and hormonal transitions, including perimenopause, thyroid function, nutrient sufficiency, and bone–metabolic resilience. The biomarkers tested are: Anti-Müllerian Hormone (AMH), Progesterone, Prolactin and Thyroid Peroxidase Antibodies (TPOAb), Free T4, Free T3, Leptin, Vitamin B12 (Cobalamin), Folate, Magnesium and Phosphate (as Phosphorus).

By layering lab data on top of continuous wearable metrics and AI-modelling, WHOOP enables members to see how biomarkers correlate with recovery trends, strain tolerance, sleep efficiency, and stress patterns over time - turning static lab results into dynamic insight.

Members will be able to purchase the Women’s Health Specialized Panel via the WHOOP app.

Hormonal Symptom Insights and Predictions

WHOOP is also expanding its Menstrual Cycle Insights and Pregnancy Insights offering, with a new update - Hormonal Symptom Insights and Predictions. Within the WHOOP app, menstruating members will now receive a personalized model of their cycle that adapts over time, based on their unique physiological data and historical patterns.

Within the WHOOP app, members will now have access to key data about their cycle that allows them to accurately adjust their daily routines, fitness regimes, and recovery practices and anticipate potential symptoms rather than simply recording them. This includes access to:

  • A dynamic date window for the next period, allowing for more anticipation around the menstrual cycle
  • Tracked trends in cycle length, period length, and variability, flagging irregular patterns before larger issues persist
  • Analyzed individual symptom patterns to anticipate when symptoms are most likely to occur

As part of the latest Cycle Insights updates, the feature now integrates with WHOOP Advanced Labs. This integration enables WHOOP to deliver personalized biomarker ranges - categorized as ‘optimal,’ ‘sufficient,’ or ‘out of range’ - based on where a member is in their cycle. When a member completes a blood draw, WHOOP automatically applies the appropriate reference range aligned to their recorded cycle phase, ensuring results are interpreted through the lens of their physiology. It’s another example of how women’s unique biology is embedded into every WHOOP product and feature.

Menstrual Cycle White Paper

WHOOP has also published a comprehensive Menstrual Cycle White Paper outlining the research, methodology, and validation behind its modeling approach. The white paper proves how continuous physiological monitoring improves prediction accuracy over time, how the system accounts for variable cycles, perimenopause, and hormonal birth control, and how prediction windows dynamically widen or narrow based on variability.

By bringing continuous, longitudinal visibility to cycle patterns, WHOOP aims to increase health literacy and close a long-standing data gap in women’s health.

“What makes this powerful isn’t any single data point - it’s how the system comes together," said Emily Capodillupo, Senior Vice President of Research, Algorithms, and Data at WHOOP. “Women don’t experience their physiology in silos. Hormones influence sleep, sleep affects recovery, and recovery shapes training response. By modeling these interactions over time - across continuous biometrics, lab data, and behavior - we can deliver guidance that reflects the full system, not just a snapshot.”

With the support of the WHOOP Medical Advisory Board, including Dr. Robin Berzin and Dr. Hazel Wallace, and in tandem with their recent collaboration with Clue, a leader in menstrual and reproductive health, WHOOP will continue to drive innovation in women’s health and deliver on the company’s goal of adding one billion healthy years to the planet.

The Women’s Health Specialized Panel, along with additional blood panels, will be available via WHOOP in April. You can find links to imagery in our Digital Press Kit.

*The Women’s Health Specialized Panel will be available exclusively in the US at launch.

About WHOOP:

WHOOP delivers a wearable membership to help people live healthier, longer lives and unlock extraordinary potential. Through a powerful 24/7 wearable with a 14-day battery life, WHOOP provides intelligent health guidance across sleep, recovery, strain, fitness, and long-term wellbeing. The health platform includes an FDA-cleared ECG, a Healthspan longevity feature, Blood Pressure Insights, and Advanced Labs blood biomarker analysis. Peer-reviewed research shows: that members who wear WHOOP daily increase their weekly exercise by more than 90 minutes, gain over two hours of additional sleep per week, and improve heart rate variability by 10%.

Trusted by millions of members worldwide including athletes, global leaders, military operators, executives, and artists, WHOOP has become a modern symbol of disciplined, intentional living. WHOOP was founded in 2012 and is headquartered in Boston. The company has raised more than $400 million in venture capital, ships to 56 countries, and operates in six languages. Learn more at whoop.com and connect with WHOOP on Instagram, LinkedIn, X, Facebook, and YouTube.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260310966566/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

One Biosciences Receives BOOST Funding From Paris-Saclay Cancer Cluster to Advance the First Single-Cell Assay Approach for ADC Therapies22.6.2026 22:15:00 CEST | Press release

One Biosciences, a techbio company pioneering clinical-grade single-cell tumor profiling, today announced financial support via a Paris-Saclay Cancer Cluster (PSCC) BOOST grant to develop the first single-cell assay for antibody-drug conjugates (ADC) therapies in oncology. The rapid growth of ADCs is driving demand for more sophisticated biomarker strategies. By capturing tumor complexity at cellular resolution, single-cell profiling has the potential to enhance patient selection and support the development of next-generation ADCs. Ultimately, it will help match the right patients to the right therapies, maximizing therapeutic benefit. The PSCC BOOST-funded project seeks to bring a new level of precision to ADC development. It will be conducted in collaboration with Adcytherix, a clinical-stage biotech company developing differentiated ADCs for cancers with high unmet medical need. The collaboration will combine Adcytherix’s expertise in ADC development with One Biosciences’ AI-powered

Interactive Brokers Expands AI Integration Capabilities – Adding ChatGPT and Grok to Its Growing Suite of Agentic Trading Tools22.6.2026 16:00:00 CEST | Press release

Additional Asset Classes Available Including Options and Futures Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the expansion of its agentic trading capabilities with the addition of ChatGPT and Grok, further broadening a growing ecosystem of AI platform integrations that began with Claude. Available through certified AI connector marketplaces across multiple leading platforms, these integrations allow clients to research, analyze, and generate instructions with speed and efficiency to uncover new trading and investing opportunities instantly. With this release, Interactive Brokers also extends the selection of products available for order instructions to include support for options, futures and futures options in addition to equities and ETFs. “We continue to see growing interest from investors in using artificial intelligence as a more natural way to interact with financial markets,” said Milan Galik, Chief Executive Officer of Interactive Brokers. “A

IQM Named Among Quantum Collaborators in HPE's New Hybrid Quantum-HPC Platform22.6.2026 15:22:00 CEST | Press release

The collaboration will advance practical and scalable hybrid classical-quantum applications. This follows IQM's first on-premises quantum computer installation in the United States, at Oak Ridge National Laboratory. IQM has sold 23 quantum systems globally to date and intends to list on Nasdaq in the United States by mid 2026. Hewlett Packard Enterprise has named IQM Quantum Computers among the companies collaborating on its hybrid classical-quantum computing platform, announced at HPE Discover Las Vegas. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260622035759/en/ IQM Radiance quantum computer at HPE Discover Las Vegas 2026 IQM, a global leader in full-stack superconducting quantum computers, is contributing superconducting quantum processor technology to the effort, in which HPE is integrating multiple quantum modalities with its Cray supercomputing infrastructure. This collaboration strengthens IQM's global expansion p

Return Abuse Goes Mainstream as Nearly Half of Consumers Use AI in Return Claims, New Riskified Research Finds22.6.2026 14:30:00 CEST | Press release

New global study shows normalization of strategic returns, widening regional differences, and rapid AI adoption reshaping ecommerce post-purchase risk Riskified (NYSE: RSKD), a global leader in ecommerce fraud detection and risk intelligence, today released a new global report, “Rewriting the Rules on Returns”, exploring how consumer attitudes and behaviors around ecommerce returns are evolving in the age of artificial intelligence (AI). The Riskified-commissioned study, conducted by eTail Insights, is based on a survey of 2,091 consumers across seven countries, alongside in-depth interviews with senior leaders from many of the largest retail companies in the world. The research finds that return abuse behaviors are increasingly normalized, while nearly half of consumers already use generative AI tools to assist with return or refund claims. At the same time, merchants are responding by tightening return policies, shortening return windows, and deploying advanced AI detection to better

Forrester Unveils Agendas For 2026 Technology & Innovation Forums In North America And EMEA22.6.2026 14:00:00 CEST | Press release

The Forums will equip technology leaders with the capabilities needed to operationalize AI and build high-performing IT organizations that deliver measurable business outcomes Forrester (Nasdaq: FORR) today announced the full conference agendas for its Technology & Innovation Forum Central (Austin, September 14–15, 2026), Technology & Innovation Forum EMEA (London, September 30–October 1, 2026), and Technology & Innovation Forum East (New York City, November 4–5, 2026). This year’s theme, “The IT Singularity,” dives into the new AI era in which AI has become ubiquitous and no longer a competitive advantage on its own. To succeed, technology leaders including chief information officers, chief data officers, and chief AI officers need to integrate AI into their operating models, modernize software development and IT operations, strengthen data and governance practices, and align technology investments with business strategy. Across the Forums, tech leaders and their teams will learn how

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye